Landscape of Push Funding in Antibiotic Research: Current Status and Way Forward
The growing need for effective antibiotics is attributed to the intrinsic ability of bacteria to develop survival mechanisms. The speed at which pathogens develop resistance is at par or even faster than the discovery of newer agents. Due to the enormous cost of developing an antibiotic and poor ret...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-7737/12/1/101 |
| _version_ | 1797445800464220160 |
|---|---|
| author | Himika Wasan Devendra Singh K.H. Reeta Yogendra Kumar Gupta |
| author_facet | Himika Wasan Devendra Singh K.H. Reeta Yogendra Kumar Gupta |
| author_sort | Himika Wasan |
| collection | DOAJ |
| description | The growing need for effective antibiotics is attributed to the intrinsic ability of bacteria to develop survival mechanisms. The speed at which pathogens develop resistance is at par or even faster than the discovery of newer agents. Due to the enormous cost of developing an antibiotic and poor return on investment, big pharmaceutical companies are stepping out of the antibiotic research field, and the world is now heading towards the silent pandemic of antibiotic resistance. Lack of investment in research has further led to the anemic antibiotic pipeline. To overcome these challenges, various organizations have come forward with push funding to financially assist antibiotic developers. Although push funding has somewhat reinvigorated the dwindled field of antibiotic development by bearing the financial risks of failure, the landscape is still large and staggered. Most of the funding is funneled towards the early stages; however, to carry the promising compounds forward, equal or more funding is required formid- and late-stage research. To some extent, the complexity associated with accessing the funding mechanisms has led to their underutilization. In the present review, we discuss several major push funding mechanisms, issues in their effective utilization, recent strategies adopted, and a way forward to streamline funding in antibiotic research. |
| first_indexed | 2024-03-09T13:31:04Z |
| format | Article |
| id | doaj.art-503e47159bb14f228e75d7383eb6db5c |
| institution | Directory Open Access Journal |
| issn | 2079-7737 |
| language | English |
| last_indexed | 2024-03-09T13:31:04Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biology |
| spelling | doaj.art-503e47159bb14f228e75d7383eb6db5c2023-11-30T21:17:23ZengMDPI AGBiology2079-77372023-01-0112110110.3390/biology12010101Landscape of Push Funding in Antibiotic Research: Current Status and Way ForwardHimika Wasan0Devendra Singh1K.H. Reeta2Yogendra Kumar Gupta3Department of Pharmacology, All India Institute of Medical Sciences, New Delhi 110029, IndiaDepartment of Pharmacology, All India Institute of Medical Sciences, New Delhi 110029, IndiaDepartment of Pharmacology, All India Institute of Medical Sciences, New Delhi 110029, IndiaPrincipal Advisor India Strategy Development, Global Antibiotics Research and Development Partnership (GARDP), New Delhi 110016, IndiaThe growing need for effective antibiotics is attributed to the intrinsic ability of bacteria to develop survival mechanisms. The speed at which pathogens develop resistance is at par or even faster than the discovery of newer agents. Due to the enormous cost of developing an antibiotic and poor return on investment, big pharmaceutical companies are stepping out of the antibiotic research field, and the world is now heading towards the silent pandemic of antibiotic resistance. Lack of investment in research has further led to the anemic antibiotic pipeline. To overcome these challenges, various organizations have come forward with push funding to financially assist antibiotic developers. Although push funding has somewhat reinvigorated the dwindled field of antibiotic development by bearing the financial risks of failure, the landscape is still large and staggered. Most of the funding is funneled towards the early stages; however, to carry the promising compounds forward, equal or more funding is required formid- and late-stage research. To some extent, the complexity associated with accessing the funding mechanisms has led to their underutilization. In the present review, we discuss several major push funding mechanisms, issues in their effective utilization, recent strategies adopted, and a way forward to streamline funding in antibiotic research.https://www.mdpi.com/2079-7737/12/1/101antibioticsantimicrobial resistancepush fundingCARB-XGARDPND4BB |
| spellingShingle | Himika Wasan Devendra Singh K.H. Reeta Yogendra Kumar Gupta Landscape of Push Funding in Antibiotic Research: Current Status and Way Forward Biology antibiotics antimicrobial resistance push funding CARB-X GARDP ND4BB |
| title | Landscape of Push Funding in Antibiotic Research: Current Status and Way Forward |
| title_full | Landscape of Push Funding in Antibiotic Research: Current Status and Way Forward |
| title_fullStr | Landscape of Push Funding in Antibiotic Research: Current Status and Way Forward |
| title_full_unstemmed | Landscape of Push Funding in Antibiotic Research: Current Status and Way Forward |
| title_short | Landscape of Push Funding in Antibiotic Research: Current Status and Way Forward |
| title_sort | landscape of push funding in antibiotic research current status and way forward |
| topic | antibiotics antimicrobial resistance push funding CARB-X GARDP ND4BB |
| url | https://www.mdpi.com/2079-7737/12/1/101 |
| work_keys_str_mv | AT himikawasan landscapeofpushfundinginantibioticresearchcurrentstatusandwayforward AT devendrasingh landscapeofpushfundinginantibioticresearchcurrentstatusandwayforward AT khreeta landscapeofpushfundinginantibioticresearchcurrentstatusandwayforward AT yogendrakumargupta landscapeofpushfundinginantibioticresearchcurrentstatusandwayforward |